Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Immune Pharmaceuticals Inc. logo — company profile

Immune Pharmaceuticals Inc.

Founded 2010 United States Fort Lee, United States 4 employees Post-IPO Equity Biotechnology, Health and Wellness +1

General Information

Company Name Immune Pharmaceuticals Inc.
Founded Year 2010
Location United States Fort Lee, United States
Employees 4
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Immune Pharmaceuticals Inc.. To contact Immune Pharmaceuticals Inc., visit immunepharmaceuticals.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Immune Pharmaceuticals Inc. compare?

A PDF of Immune Pharmaceuticals Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Immune Pharmaceuticals Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company focused on developing innovative therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's primary program, bertilimumab, is a first-in-class, fully human monoclonal antibody designed to target and reduce levels of eotaxin-1, a chemokine involved in immune responses and eosinophil attraction to inflammatory sites. By neutralizing eotaxin-1, bertilimumab has the potential to alleviate inflammatory conditions by preventing the migration of eosinophils and other cells. Immune is currently conducting two phase 2 clinical trials to evaluate the efficacy of bertilimumab in patients with bullous pemphigoid and ulcerative colitis, with potential applications in atopic dermatitis, asthma, and other diseases. Additionally, the company is advancing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is in late-stage preclinical testing. Founded in 2010 and headquartered in the United States, Immune Pharmaceuticals presents an intriguing opportunity for investment in the biotechnology, health and wellness, and pharmaceutical sectors. Investors should monitor the progress of Immune's clinical trials and the development of their proprietary therapies for potential investment opportunities.

No funding data available for Immune Pharmaceuticals Inc. yet.

Immune Pharmaceuticals Inc. Alternatives & Competitors

View All Alternatives
Immune Pharmaceuticals Inc. vs
Polymed Biopharmaceuticals
Polymed Biopharmaceuticals China

Polymed creates novel PROTAC therapies for cancers and immunology HPB-143 (IRAK4) & HPB-092 (FLT3/...

Series A
2 employees
Biotechnology, Pharmaceutical
Immune Pharmaceuticals Inc. vs
Entero Therapeutics (Nasdaq: ENTO)
Entero Therapeutics (Nasdaq: ENTO) United States

A biopharma company focused on the development of targeted, non-systemic therapies for gastrointesti...

Post-IPO Equity
12 employees
Biotechnology, Health Care
Immune Pharmaceuticals Inc. vs
Applied Molecular Transport
Applied Molecular Transport United States

We are committed to developing transformational biologic medicines to serve patients with debilitati...

Post-IPO Equity
17 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin...
Immune Pharmaceuticals Inc. was founded in 2010.
Immune Pharmaceuticals Inc. is headquartered in Fort Lee, United States.
Immune Pharmaceuticals Inc. operates in Biotechnology, Health and Wellness and Pharmaceutical.
Immune Pharmaceuticals Inc. has approximately 4 employees.
Top alternatives and competitors to Immune Pharmaceuticals Inc. include Polymed Biopharmaceuticals, Entero Therapeutics (Nasdaq: ENTO), Applied Molecular Transport, PlantEXT Ltd., OSE Immunotherapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Immune Pharmaceuticals Inc. and Polymed Biopharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Immune Pharmaceuticals Inc., https://bouncewatch.com/company/immune-pharmaceuticals, updated 7 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout